GlassScriptPhysician profile
Melissa Rudge
NPI 1326520966
$3,944.77
in general payments reported to CMS, 2019-2025
26 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2022: $546 · 2023: $495 · 2024: $1,233 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.40 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $401.98 | 2023-2025 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $401.42 | 2021-2022 | |
| Alkermes, INC. | $249.89 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $196.06 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $160.28 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $138.79 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $134.53 | 2024-2025 | Qelbree |
| Lundbeck LLC | $123.31 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $119.66 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.02 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $112.99 | 2022-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $100.09 | 2024-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $98.14 | 2024-2025 | Hetlioz, Fanapt |
| Amgen INC. | $31.96 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $31.08 | 2022 | |
| Noven Therapeutics, LLC | $29.74 | 2024 | Secuado, Xelstrym |
| Corium, LLC | $26.83 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $20.90 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.45 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $19.29 | 2024 | Invega Sustenna |
| Abbott Laboratories | $17.65 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $16.68 | 2022 | |
| Lilly USA, LLC | $15.64 | 2022 | |
| Dexcom, INC. | $15.63 | 2022 | |
| Neuronetics, INC. | $14.36 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Rudge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.